Compare ING Groep NV (ING) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Natera Inc. Common Stock — how do they compare? ING Groep NV trades at $33.08 (market cap $95.72B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: ING Groep NV is the larger of the two by market cap, and ING Groep NV pays a 3.95% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and Natera Inc. Common Stock for 0 Days on average.
| ING | NTRA | |
|---|---|---|
Market Cap | $95.72B | $57.03B |
Volume | 2,335,394 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $37.27 | $425.64 |
52-Week Low | $23.66 | $179.42 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $235.88B | $56.18B |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.63, up 0.72% today, with a bearish technical signal but strong fundamentals including a 28.34% net income margin and consistent earnings beats. Recent news highlights management's raised ROE target above 16% for 2027, driven by revenue growth and AI initiatives. Cash flow trends show volatile net outflows, with 2025 net cash flow at -$14.92 billion.
The outlook is mixed: analyst consensus is bullish with 65% buy ratings, but technical indicators and cash flow volatility pose risks. Upside potential hinges on execution of growth strategies and cost discipline, while regulatory scrutiny and macroeconomic pressures remain key watchpoints for investors.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
